Table 1 Characteristics of patients with NPC in the training and validation cohorts. NE, neutrophil; LYM, lymphocytes; SII, systemic immune-infammation; PLR, Platelet-to-Lymphocyte ratio; NLR, Neutrophil-to-Lymphocyte ratio; LMR, Lymphocyte-to-Monocyte ratio; GTVnx gross, tumor volume of the nasopharynx; GTV70, gross tumor volume receiving 70 gy.

Age (Years)

0.942

≥ 60

51

21

< 60

74

33

Gender

0.370

Male

90

35

Female

35

19

Pathologic Classification

0.192

Type I

5

2

Type II

12

6

Type III

108

46

T Stage

0.204

T1

10

3

T2

17

12

T3

62

19

T4a

36

20

N Stage

0.202

N0

3

5

N1

27

11

N2

63

28

N3

32

10

Clinical stages

0.803

II

7

3

III

56

24

IVa

62

27

WBC (10¹²/L)

0.142

Mean (SD)

6.77

5.91

Median [Min, Max]

6.00 [2.02, 21.13]

4.95 [2.14, 29.92]

RBC (10¹²/L)

0.998

Mean (SD)

4.42

4.42

Median [Min, Max]

4.46 [3.00, 5.58]

4.24 [3.01, 8.71]

PLT (10⁹/L)

0.891

Mean (SD)

185.73

176.70

Median [Min, Max]

176 [72, 498]

168.50 [63, 347]

NE (10⁹/L)

0.239

Mean (SD)

5.05

4.40

Median [Min, Max]

4.18 [0.95, 19.42]

3.77 [1.52, 27.13]

LMR

0.603

Mean (SD)

12.15

14.17

Median [Min, Max]

7.56 [0.6, 105.5]

6.45 [0.847, 109.1]

NLR

0.078

Mean (SD)

4.92

4.05

Median [Min, Max]

4.17 [0.55, 17.49]

3.10 [0.96, 12.88]

PLR

0.696

Mean (SD)

0.03

0.03

Median [Min, Max]

0.02 [0.04, 0.12]

0.02 [0.01, 0.16]

SII

0.101

Mean (SD)

918.64

728.18

Median [Min, Max]

654 [85.22, 4477.75]

536.70 [135.32, 3137.91]

EGFR

0.709

Negative

61

24

Positive

64

30

EBER

0.521

Negative

40

19

Positive

85

35

Targeted Therapy

0.685

No

73

34

Yes

52

20

Inducing Chemotherapy

0.614

No

14

4

Yes

111

50

Concurrent Chemotherapy

0.983

No

57

24

Yes

68

30

GTVnx

0.524

Mean (SD)

70.32

70.17

Median [Min, Max]

70.32 [59.75, 74.08]

70.26 [64.99, 72.27]

GTV70

0.682

Mean (SD)

70.11

70.03

Median [Min, Max]

70.26 [57.89, 73.00]

70.20 [66.22, 72.04]

Post-Treatment Evaluation

0.758

Residual

31

12

Non-Residual

94

42